OncoGenex shares jump on trial plans

Shares of Bothell, WA-based OncoGenex jumped on the news that it's planning to proceed with late-stage trials of a prostate cancer therapy dubbed OGX-011. The company earned some kudos from Rodman & Renshaw analyst Simos Simeonidis, who said "We would like to point out that this is a very small team that got to the point where many biotechs dream of." Shares rose about 15 percent. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.